MedTrace Logo

Optimize Heart Failure Care During TRANSitional Period in Patients With Acute Heart Failure.

NCT04900584 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1009

Last updated 2022-06-01

No results posted yet for this study

Summary

The period of about a month after the discharge of acute heart failure patients is defined as a transition time. During this period, the patient has a high mortality rate and a readmission rate because the patient is not stabilized. In the United States and Europe, the readmission rate is more than 25% within 30 days, and the mortality rate within 30 days after discharge is three times that of patients with chronic heart failure.

The TRANS-HF is a prospective, randomized, multi-center, controlled study, which enrolls patients with acute heart failure with reduced ejection fraction.

The objective of TRANS-HF is to improve GAI at six months through three interventions: pre-discharge checklist, heart failure education, and telephone monitoring before the first outpatient visit.

Conditions

  • Heart Failure With Reduced Ejection Fraction
  • Acute Heart Failure

Interventions

OTHER

Checklist

Checklist of guideline-based treatment before discharge

OTHER

Education

Heart failure education before discharge

OTHER

Telephone monitoring

Telephone monitoring after discharge

Sponsors & Collaborators

  • Korean Center for Disease Control and Prevention

    collaborator OTHER_GOV

  • Wonju Severance Christian Hospital

    lead OTHER

Principal Investigators

  • Byung-Su Yoo, MD, PhD · Wonju Severance Christian Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-23
Primary Completion
2022-10-31
Completion
2023-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04900584 on ClinicalTrials.gov